Trial | NCT01979926  Report issue

Title

Comparative Evaluate the Efficacy to Acute and Chronic Bronchitis
Double-blind, A Multicenter, Randomized, Placebo-controlled, Parallel, Phase 2 Study to Comparative Evaluate the Efficacy of N02RS1 600mg/Day, 12,00mg/Day in Korean Patients With Acute and Chronic Bronchitis

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    102
The Purpose of A Multicenter, Randomized, Double-blind, Placebo-controlled to Evaluate the Efficacy, Safety and Pharmacokinetics of N02RS1 600mg and 1,200mg per day in Patients With acute and acute exacerbation of chronic bronchitis for 7 days.
Study Started
Nov 30
2013
Primary Completion
Nov 30
2013
Study Completion
Mar 31
2014
Last Update
May 30
2014
Estimate

Drug Combination of Broussonetia spp and Lonicera spp

600 mg/ day or 1200 mg/ day for 7 days

  • Other names: N02RS1

N02RS1 200mg Experimental

Combination of Broussonetia spp and Lonicera spp

N02RS1 400mg Experimental

Combination of Broussonetia spp and Lonicera spp

Placebo Placebo Comparator

Sugar pill

Criteria 

Inclusion Criteria:

Patients over 18, under 75 years of age
Patients Acute and Chronic Bronchitis

Exclusion Criteria:

Patients who have gotten a glucocorticoids treatment within 4 weeks.
Patients who need treatments of antibiotic and acute bronchitis infection.
Patients who have gotten teatments of antibiotic,bronchodilator,painkiller and secretagog within 7 days.
Bronchial asthma patient.
Patients who have an indication of bleeding.
Patients who have a serious heart and renal disease or liver ailment or immunosuppressive response.
Patients who have history of over 3 phage of Chronic obstructiv lung disease
Bronchiectasis patients.
No Results Posted